menu
    • menu

    Company profile for Neurocrine Biosciences

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development program...
    Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurocrine BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130
    Telephone
    Telephone
    1-858-617-7600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurocrine.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurocrine's Review Contrasts Tardive Dyskinesia Drugs
    Neurocrine's Review Contrasts Tardive Dyskinesia Drugs

    23 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/rd/neurocrine-review-highlights-key-differences-between-tardive-dyskinesia-drugs-18317

    INDPHARMAPOST
    23 Nov 2025
    Share Share
    Neurocrine Publishes Review Highlighting Unique INGREZZA Profile
    Neurocrine Publishes Review Highlighting Unique INGREZZA Profile

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-landmark-narrative-review-on-fda-approved-vmat2-inhibitors-demonstrating-unique-profile-of-ingrezza-valbenazine-capsules-302620990.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Neurocrine Biosciences To Present At Investor Conferences
    Neurocrine Biosciences To Present At Investor Conferences

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-302611943.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Neurocrine Biosciences Updates Phase 2 Study Of NBI-1070770
    Neurocrine Biosciences Updates Phase 2 Study Of NBI-1070770

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-provides-update-on-phase-2-study-of-nbi-1070770-in-adults-with-major-depressive-disorder-302610643.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail
    Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail

    11 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/neurocrines-depression-drug-latest-asset-takeda-pact-flunk-phase-2-trial

    FIERCE BIOTECH
    11 Nov 2025
    Share Share
    Neurocrine Pens $880M Pact With Transthera For Immunology Target
    Neurocrine Pens $880M Pact With Transthera For Immunology Target

    04 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/neurocrine-pens-880m-deal-chinas-transthera-red-hot-immunology-target

    FIERCE BIOTECH
    04 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search